DD&D: The true cost of steroid-toxicity
John Stone, MD MPH, Chair of Steritas Scientific Board, discusses the true cost of steroid-toxicity with Drug Discovery & Development (DD&D). Read the full article here.
Pharmafocus: Opportunities to reduce steroid-toxicity and embrace new treatment options for autoimmune patients
Steritas' John Stone analyses the benefits that a quantifiable index system can have for researchers looking into steroid toxicity, and how this can allow them to work with larger sets of patient ...
JCS: An Interview With Dr John Stone, Steritas
The Journal for Clinical Studies (JCS) sat down with John Stone, MD MPH, Chair of the Steritas Scientific Board, to discuss the steroid-toxicity epidemic. Read the full interview, which begins on ...
DDW: Industry trends and predictions for 2025
Megan Thomas of Drug Discovery World (DDW) spoke with Martha Stone, CEO of Steritas, and other industry experts about their predictions for drug discovery opportunities in 2025. Read the article here.
Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics
First-in-class steroid-toxicity outcome assessments licensed by argenx to support the development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: ...
Alder-Hey Children’s NHS Foundation Trust and Liverpool Clinical Trials Centre led clinical trial to compare effectiveness and to assess steroid-toxicity in children with juvenile idiopathic arthritis
Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children Boston, MA, USA, 24 September 2024: Steritas LLC., a company dedicated to enhancing ...